ribosomal protein L12 pseudogene 4Genealiases: RPL12_23_1714 · dJ800C24.1
Q-omics provides the consensus-scored RPL12P4 profile across patient tissues and cancer cell-line models. RPL12P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL12P4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RPL12P4 RNA expression shows 10,631 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, COAD, and ACC as cancer lineages where RPL12P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P4 survival associations across molecular data types. RPL12P4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P4 RNA expression–survival associations across cancer types. High RPL12P4 expression shows unfavorable associations in KIRP and ACC, but favorable associations in THCA, KIRC, SKCM and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL12P4 RNA expression.
This table summarizes RPL12P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P4 shows lower tumor expression in BRCA and higher tumor expression in COAD, KIRP, KIRC, CHOL and LIHC. The COAD box plot shows higher RPL12P4 RNA expression in tumor versus normal tissue (log2 FC = +1.072, t-test p < 0.001).
This table shows molecular features associated with RPL12P4 in patient tissues and cancer cell lines. In patient samples, RPL12P4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
